Clin2Atlas
AtlasPregnancy & newbornsNeonatal disorders

Neonatal sepsis and other neonatal infections

4Curable or preventable in mostAI-generated

Most neonatal sepsis is curable or preventable with timely care.AI-generated

Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251989 — Epoetin alfa approved (FDA)1989 — Cefmetazole approved (FDA)1989 — Cefpiramide approved (FDA)1989 — Omeprazole approved (FDA)1989 — Ganciclovir approved (FDA)1989 — Cefixime approved (FDA)1989 — Mefloquine approved (FDA)1990 — Ofloxacin approved (FDA)1990 — Podofilox approved (FDA)1990 — Levamisole approved (FDA)1990 — Fluticasone propionate approved (FDA)1990 — Fluconazole approved (FDA)1991 — Azithromycin approved (FDA)1991 — Clarithromycin approved (FDA)1991 — Filgrastim approved (FDA)1991 — Enoxacin approved (FDA)1991 — Cefprozil anhydrous, (e)- approved (FDA)1991 — Foscarnet approved (FDA)1991 — Loracarbef anhydrous approved (FDA)1991 — Didanosine approved (FDA)1992 — Atovaquone approved (FDA)1992 — Rifabutin approved (FDA)1992 — Halofantrine approved (FDA)1992 — Itraconazole approved (FDA)1992 — Zalcitabine approved (FDA)1992 — Terbinafine approved (FDA)1992 — Temafloxacin approved (FDA)1992 — Lomefloxacin approved (FDA)1992 — Paclitaxel approved (FDA)1993 — Rimantadine approved (FDA)1993 — Tazobactam approved (FDA)1994 — Stavudine approved (FDA)1994 — Famciclovir approved (FDA)1994 — Salmeterol approved (FDA)1994 — Budesonide approved (FDA)1995 — Saquinavir approved (FDA)1995 — Dirithromycin approved (FDA)1995 — Ceftibuten approved (FDA)1995 — Valacyclovir approved (FDA)1995 — Lamivudine approved (FDA)1996 — Penciclovir approved (FDA)1996 — Sparfloxacin approved (FDA)1996 — Meropenem approved (FDA)1996 — Levofloxacin anhydrous approved (FDA)1996 — Hepatitis b virus hbsag surface protein antigen approved (FDA)1996 — Indinavir anhydrous approved (FDA)1996 — Diphtheria toxoid approved (FDA)1996 — Tetanus toxoid approved (FDA)1996 — Cidofovir anhydrous approved (FDA)1996 — Albendazole approved (FDA)1996 — Fosfomycin approved (FDA)1996 — Butenafine approved (FDA)1996 — Ivermectin approved (FDA)1996 — Nevirapine approved (FDA)1996 — Ritonavir approved (FDA)1996 — Cefepime approved (FDA)1997 — Imiquimod approved (FDA)1997 — Trovafloxacin approved (FDA)1997 — Grepafloxacin approved (FDA)1997 — Cefdinir approved (FDA)1997 — Nelfinavir approved (FDA)1997 — Sulesomab approved (FDA)1997 — Bordetella pertussis pertactin autotransporter approved (FDA)1997 — Alatrofloxacin approved (FDA)1997 — Delavirdine approved (FDA)1997 — Bordetella pertussis filamentous hemagglutinin approved (FDA)1997 — Interferon alfacon-1 approved (FDA)1998 — Palivizumab approved (FDA)1998 — Efavirenz approved (FDA)1998 — Rifapentine approved (FDA)1998 — Etanercept approved (FDA)1998 — Celecoxib approved (FDA)1998 — Abacavir approved (FDA)1999 — Oseltamivir approved (FDA)1999 — Zanamivir approved (FDA)1999 — Gatifloxacin approved (FDA)1999 — Bordetella pertussis toxin approved (FDA)1999 — Fomivirsen approved (FDA)1999 — Rotavirus, live attenuated approved (FDA)1999 — Alitretinoin approved (FDA)1999 — Amprenavir approved (FDA)1999 — Moxifloxacin approved (FDA)2000 — Lopinavir approved (FDA)2000 — Linezolid approved (FDA)2000 — Docosanol approved (FDA)2000 — Peginterferon alfa-2b approved (FDA)2000 — Proguanil approved (FDA)2000 — Hepatitis b virus s protein, pre-s1 protein and pre-s2 protein virus like particles approved (FDA)2000 — Isopropyl alcohol approved (FDA)2000 — Pyrethrum extract approved (FDA)2001 — Valganciclovir approved (FDA)2001 — Cefditoren pivoxil approved (FDA)2001 — Telithromycin approved (FDA)2001 — Caspofungin approved (FDA)2001 — Tenofovir disoproxil approved (FDA)2001 — Anakinra approved (FDA)2001 — Ertapenem approved (FDA)2001 — Drotrecogin alfa (activated) approved (FDA)2001 — Streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae crm197 approved (FDA)2001 — Formoterol approved (FDA)2002 — Adalimumab approved (FDA)2002 — Voriconazole approved (FDA)2002 — Adefovir dipivoxil approved (FDA)2002 — Pegfilgrastim approved (FDA)2002 — Peginterferon alfa-2a approved (FDA)2002 — Nitazoxanide approved (FDA)2002 — Guaifenesin approved (FDA)2003 — Sertaconazole approved (FDA)2003 — Gemifloxacin approved (FDA)2003 — Fosamprenavir approved (FDA)2003 — Omalizumab approved (FDA)2003 — Daptomycin approved (FDA)2003 — Enfuvirtide approved (FDA)2003 — Emtricitabine approved (FDA)2003 — Atazanavir approved (FDA)2004 — Tiotropium approved (FDA)2004 — Rifaximin approved (FDA)2004 — Vibrio cholerae toxin b subunit approved (FDA)2004 — Tinidazole approved (FDA)2004 — Vibrio cholerae, inactivated approved (FDA)2005 — Posaconazole approved (FDA)2005 — Tigecycline approved (FDA)2005 — Entecavir anhydrous approved (FDA)2005 — Micafungin approved (FDA)2005 — Quinine approved (FDA)2005 — Tocilizumab approved (FDA)2005 — Tipranavir approved (FDA)2006 — Measles virus, live attenuated approved (FDA)2006 — Darunavir approved (FDA)2006 — Telbivudine approved (FDA)2006 — Bismuth subcitrate potassium approved (FDA)2006 — Arformoterol approved (FDA)2006 — Human papillomavirus, l1 protein virus like particles approved (FDA)2006 — Mumps virus, live attenuated approved (FDA)2006 — Rotavirus, live approved (FDA)2006 — Rubella virus, live attenuated approved (FDA)2006 — Sinecatechins approved (FDA)2006 — Anidulafungin approved (FDA)2006 — Varicella zoster virus, live attenuated approved (FDA)2007 — Retapamulin approved (FDA)2007 — Doripenem approved (FDA)2007 — Influenza b virus, inactivated neuraminidase approved (FDA)2007 — Influenza b virus, inactivated hemagglutinin approved (FDA)2007 — Influenza a virus, inactivated neuraminidase approved (FDA)2007 — Influenza a virus, inactivated hemagglutinin approved (FDA)2007 — Maraviroc approved (FDA)2007 — Influenza a virus, inactivated whole virion approved (FDA)2007 — Raltegravir approved (FDA)2008 — Etravirine approved (FDA)2008 — Eltrombopag approved (FDA)2008 — Menthol approved (FDA)2008 — Influenza a virus, split virion approved (FDA)2009 — Hepatitis b immune globulin approved (FDA)2009 — Indacaterol approved (FDA)2009 — Streptococcus pneumoniae polysaccharide conjugated to haemophilus influenzae protein d approved (FDA)2009 — Golimumab approved (FDA)2009 — Streptococcus pneumoniae polysaccharide conjugated to tetanus toxoid approved (FDA)2009 — Japanese encephalitis virus, inactivated approved (FDA)2009 — Telavancin approved (FDA)2009 — Besifloxacin approved (FDA)2009 — Artemether approved (FDA)2009 — Benzyl alcohol approved (FDA)2009 — Lumefantrine approved (FDA)2009 — Streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae toxoid approved (FDA)2009 — Influenza b virus, split virion approved (FDA)2010 — Tesamorelin approved (FDA)2010 — Neisseria meningitidis oligosaccharide conjugated to corynebacterium diphtheriae crm197 approved (FDA)2010 — Besilesomab approved (FDA)2010 — Roflumilast approved (FDA)2010 — Ceftaroline fosamil approved (FDA)2011 — Boceprevir approved (FDA)2011 — Spinosad approved (FDA)2011 — Influenza b virus, live attenuated approved (FDA)2011 — Influenza a virus, live attenuated approved (FDA)2011 — Fidaxomicin approved (FDA)2011 — Telaprevir approved (FDA)2011 — Methylene blue cation approved (FDA)2011 — Rilpivirine approved (FDA)2012 — Cobicistat approved (FDA)2012 — Bedaquiline approved (FDA)2012 — Raxibacumab approved (FDA)2012 — Neisseria meningitidis polysaccharide conjugated to tetanus toxoid approved (FDA)2012 — Aclidinium approved (FDA)2012 — Elvitegravir approved (FDA)2013 — Neisseria meningitidis factor h binding protein approved (FDA)2013 — Dolutegravir approved (FDA)2013 — Neisseria meningitidis adhesin a approved (FDA)2013 — Vilanterol approved (FDA)2013 — Vaccinia virus, live modified approved (FDA)2013 — Neisseria meningitidis outer membrane vesicles approved (FDA)2013 — Umeclidinium approved (FDA)2013 — Luliconazole approved (FDA)2013 — Neisseria meningitidis neisserial heparin binding antigen approved (FDA)2013 — Simeprevir approved (FDA)2013 — Sofosbuvir approved (FDA)2014 — Paritaprevir approved (FDA)2014 — Ledipasvir approved (FDA)2014 — Oritavancin approved (FDA)2014 — Ceftolozane approved (FDA)2014 — Peramivir anhydrous approved (FDA)2014 — Olodaterol approved (FDA)2014 — Tavaborole approved (FDA)2014 — Efinaconazole approved (FDA)2014 — Miltefosine approved (FDA)2014 — Dalbavancin approved (FDA)2014 — Vasopressin approved (FDA)2014 — Daclatasvir approved (FDA)2014 — Asunaprevir approved (FDA)2014 — Tedizolid phosphate approved (FDA)2014 — Delamanid approved (FDA)2014 — Dasabuvir approved (FDA)2014 — Ombitasvir approved (FDA)2015 — Avibactam approved (FDA)2015 — Tenofovir alafenamide approved (FDA)2015 — Isavuconazonium approved (FDA)2016 — Bezlotoxumab approved (FDA)2016 — Velpatasvir approved (FDA)2016 — Ephedrine approved (FDA)2016 — Obiltoxaximab approved (FDA)2016 — Grazoprevir anhydrous approved (FDA)2016 — Elbasvir approved (FDA)2017 — Delafloxacin approved (FDA)2017 — Benznidazole approved (FDA)2017 — Letermovir approved (FDA)2017 — Dupilumab approved (FDA)2017 — Avelumab approved (FDA)2017 — Vaborbactam approved (FDA)2017 — Angiotensin ii approved (FDA)2017 — Secnidazole approved (FDA)2017 — Ozenoxacin approved (FDA)2017 — Pibrentasvir approved (FDA)2017 — Hydrogen peroxide approved (FDA)2017 — Glecaprevir approved (FDA)2017 — Voxilaprevir approved (FDA)2017 — Lotilaner approved (FDA)2018 — Eravacycline approved (FDA)2018 — Varicella zoster virus envelope glycoprotein e approved (FDA)2018 — Baloxavir marboxil approved (FDA)2018 — Ibalizumab approved (FDA)2018 — Chimeric yellow fever dengue virus, live attenuated approved (FDA)2018 — Tecovirimat approved (FDA)2018 — Bictegravir approved (FDA)2018 — Plazomicin approved (FDA)2018 — Omadacycline approved (FDA)2018 — Moxidectin approved (FDA)2018 — Rifamycin approved (FDA)2018 — Tafenoquine approved (FDA)2018 — Sarecycline approved (FDA)2018 — Doravirine approved (FDA)2019 — Lefamulin approved (FDA)2019 — Triclabendazole approved (FDA)2019 — Vesicular stomatitis virus encoding ebola virus glycoprotein approved (FDA)2019 — Pretomanid approved (FDA)2019 — Relebactam anhydrous approved (FDA)2019 — Cefiderocol approved (FDA)2020 — Influenza b virus hemagglutinin approved (FDA)2020 — Fostemsavir approved (FDA)2020 — Ansuvimab approved (FDA)2020 — Remdesivir approved (FDA)2020 — Tozinameran approved (FDA)2020 — Artesunate approved (FDA)2020 — Atoltivimab approved (FDA)2020 — Maftivimab approved (FDA)2020 — Odesivimab approved (FDA)2020 — Adenovirus type 26 encoding ebola virus glycoprotein approved (FDA)2020 — Vaccinia virus, modified encoding ebola virus glycoprotein and nucleoprotein approved (FDA)2020 — Nifurtimox approved (FDA)2020 — Influenza a virus hemagglutinin approved (FDA)2020 — Abametapir approved (FDA)2020 — Vibrio cholerae, live attenuated approved (FDA)2021 — Idecabtagene vicleucel approved (FDA)2021 — Sars-cov-2 virus spike protein approved (FDA)2021 — Adenovirus type 26 encoding sars-cov-2 spike glycoprotein approved (FDA)2021 — Sotrovimab approved (FDA)2021 — Regdanvimab approved (FDA)2021 — Ibrexafungerp approved (FDA)2021 — Elasomeran approved (FDA)2021 — Maribavir approved (FDA)2021 — Chimpanzee adenovirus encoding sars-cov-2 spike glycoprotein approved (FDA)2021 — Brincidofovir approved (FDA)2021 — Cabotegravir approved (FDA)2021 — Fexinidazole approved (FDA)2022 — Dengue virus, live attenuated approved (FDA)2022 — Lenacapavir approved (FDA)2022 — Oteseconazole approved (FDA)2022 — Tabelecleucel approved (FDA)2022 — Sars-cov-2 virus, inactivated approved (FDA)2023 — Respiratory syncytial virus pre-fusion glycoprotein f approved (FDA)2023 — Rezafungin approved (FDA)2023 — Bacillus anthracis protective antigen, adsorbed approved (FDA)2023 — Chikungunya virus, live attenuated approved (FDA)2023 — Cantharidin approved (FDA)2023 — Selvacovatein approved (FDA)2023 — Fecal microbiota spores, live approved (FDA)2023 — Retifanlimab approved (FDA)2024 — Amdinocillin pivoxil approved (FDA)2024 — Ceftobiprole medocaril free acid approved (FDA)2024 — Respiratory syncytial virus pre-fusion glycoprotein f mrna approved (FDA)2024 — Polihexanide approved (FDA)2024 — Berdazimer sodium approved (FDA)
1989: Drug approval — Epoetin alfa approved (FDA). 1989: Drug approval — Cefmetazole approved (FDA). 1989: Drug approval — Cefpiramide approved (FDA). 1989: Drug approval — Omeprazole approved (FDA). 1989: Drug approval — Ganciclovir approved (FDA). 1989: Drug approval — Cefixime approved (FDA). 1989: Drug approval — Mefloquine approved (FDA). 1990: Drug approval — Ofloxacin approved (FDA). 1990: Drug approval — Podofilox approved (FDA). 1990: Drug approval — Levamisole approved (FDA). 1990: Drug approval — Fluticasone propionate approved (FDA). 1990: Drug approval — Fluconazole approved (FDA). 1991: Drug approval — Azithromycin approved (FDA). 1991: Drug approval — Clarithromycin approved (FDA). 1991: Drug approval — Filgrastim approved (FDA). 1991: Drug approval — Enoxacin approved (FDA). 1991: Drug approval — Cefprozil anhydrous, (e)- approved (FDA). 1991: Drug approval — Foscarnet approved (FDA). 1991: Drug approval — Loracarbef anhydrous approved (FDA). 1991: Drug approval — Didanosine approved (FDA). 1992: Drug approval — Atovaquone approved (FDA). 1992: Drug approval — Rifabutin approved (FDA). 1992: Drug approval — Halofantrine approved (FDA). 1992: Drug approval — Itraconazole approved (FDA). 1992: Drug approval — Zalcitabine approved (FDA). 1992: Drug approval — Terbinafine approved (FDA). 1992: Drug approval — Temafloxacin approved (FDA). 1992: Drug approval — Lomefloxacin approved (FDA). 1992: Drug approval — Paclitaxel approved (FDA). 1993: Drug approval — Rimantadine approved (FDA). 1993: Drug approval — Tazobactam approved (FDA). 1994: Drug approval — Stavudine approved (FDA). 1994: Drug approval — Famciclovir approved (FDA). 1994: Drug approval — Salmeterol approved (FDA). 1994: Drug approval — Budesonide approved (FDA). 1995: Drug approval — Saquinavir approved (FDA). 1995: Drug approval — Dirithromycin approved (FDA). 1995: Drug approval — Ceftibuten approved (FDA). 1995: Drug approval — Valacyclovir approved (FDA). 1995: Drug approval — Lamivudine approved (FDA). 1996: Drug approval — Penciclovir approved (FDA). 1996: Drug approval — Sparfloxacin approved (FDA). 1996: Drug approval — Meropenem approved (FDA). 1996: Drug approval — Levofloxacin anhydrous approved (FDA). 1996: Drug approval — Hepatitis b virus hbsag surface protein antigen approved (FDA). 1996: Drug approval — Indinavir anhydrous approved (FDA). 1996: Drug approval — Diphtheria toxoid approved (FDA). 1996: Drug approval — Tetanus toxoid approved (FDA). 1996: Drug approval — Cidofovir anhydrous approved (FDA). 1996: Drug approval — Albendazole approved (FDA). 1996: Drug approval — Fosfomycin approved (FDA). 1996: Drug approval — Butenafine approved (FDA). 1996: Drug approval — Ivermectin approved (FDA). 1996: Drug approval — Nevirapine approved (FDA). 1996: Drug approval — Ritonavir approved (FDA). 1996: Drug approval — Cefepime approved (FDA). 1997: Drug approval — Imiquimod approved (FDA). 1997: Drug approval — Trovafloxacin approved (FDA). 1997: Drug approval — Grepafloxacin approved (FDA). 1997: Drug approval — Cefdinir approved (FDA). 1997: Drug approval — Nelfinavir approved (FDA). 1997: Drug approval — Sulesomab approved (FDA). 1997: Drug approval — Bordetella pertussis pertactin autotransporter approved (FDA). 1997: Drug approval — Alatrofloxacin approved (FDA). 1997: Drug approval — Delavirdine approved (FDA). 1997: Drug approval — Bordetella pertussis filamentous hemagglutinin approved (FDA). 1997: Drug approval — Interferon alfacon-1 approved (FDA). 1998: Drug approval — Palivizumab approved (FDA). 1998: Drug approval — Efavirenz approved (FDA). 1998: Drug approval — Rifapentine approved (FDA). 1998: Drug approval — Etanercept approved (FDA). 1998: Drug approval — Celecoxib approved (FDA). 1998: Drug approval — Abacavir approved (FDA). 1999: Drug approval — Oseltamivir approved (FDA). 1999: Drug approval — Zanamivir approved (FDA). 1999: Drug approval — Gatifloxacin approved (FDA). 1999: Drug approval — Bordetella pertussis toxin approved (FDA). 1999: Drug approval — Fomivirsen approved (FDA). 1999: Drug approval — Rotavirus, live attenuated approved (FDA). 1999: Drug approval — Alitretinoin approved (FDA). 1999: Drug approval — Amprenavir approved (FDA). 1999: Drug approval — Moxifloxacin approved (FDA). 2000: Drug approval — Lopinavir approved (FDA). 2000: Drug approval — Linezolid approved (FDA). 2000: Drug approval — Docosanol approved (FDA). 2000: Drug approval — Peginterferon alfa-2b approved (FDA). 2000: Drug approval — Proguanil approved (FDA). 2000: Drug approval — Hepatitis b virus s protein, pre-s1 protein and pre-s2 protein virus like particles approved (FDA). 2000: Drug approval — Isopropyl alcohol approved (FDA). 2000: Drug approval — Pyrethrum extract approved (FDA). 2001: Drug approval — Valganciclovir approved (FDA). 2001: Drug approval — Cefditoren pivoxil approved (FDA). 2001: Drug approval — Telithromycin approved (FDA). 2001: Drug approval — Caspofungin approved (FDA). 2001: Drug approval — Tenofovir disoproxil approved (FDA). 2001: Drug approval — Anakinra approved (FDA). 2001: Drug approval — Ertapenem approved (FDA). 2001: Drug approval — Drotrecogin alfa (activated) approved (FDA). 2001: Drug approval — Streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae crm197 approved (FDA). 2001: Drug approval — Formoterol approved (FDA). 2002: Drug approval — Adalimumab approved (FDA). 2002: Drug approval — Voriconazole approved (FDA). 2002: Drug approval — Adefovir dipivoxil approved (FDA). 2002: Drug approval — Pegfilgrastim approved (FDA). 2002: Drug approval — Peginterferon alfa-2a approved (FDA). 2002: Drug approval — Nitazoxanide approved (FDA). 2002: Drug approval — Guaifenesin approved (FDA). 2003: Drug approval — Sertaconazole approved (FDA). 2003: Drug approval — Gemifloxacin approved (FDA). 2003: Drug approval — Fosamprenavir approved (FDA). 2003: Drug approval — Omalizumab approved (FDA). 2003: Drug approval — Daptomycin approved (FDA). 2003: Drug approval — Enfuvirtide approved (FDA). 2003: Drug approval — Emtricitabine approved (FDA). 2003: Drug approval — Atazanavir approved (FDA). 2004: Drug approval — Tiotropium approved (FDA). 2004: Drug approval — Rifaximin approved (FDA). 2004: Drug approval — Vibrio cholerae toxin b subunit approved (FDA). 2004: Drug approval — Tinidazole approved (FDA). 2004: Drug approval — Vibrio cholerae, inactivated approved (FDA). 2005: Drug approval — Posaconazole approved (FDA). 2005: Drug approval — Tigecycline approved (FDA). 2005: Drug approval — Entecavir anhydrous approved (FDA). 2005: Drug approval — Micafungin approved (FDA). 2005: Drug approval — Quinine approved (FDA). 2005: Drug approval — Tocilizumab approved (FDA). 2005: Drug approval — Tipranavir approved (FDA). 2006: Drug approval — Measles virus, live attenuated approved (FDA). 2006: Drug approval — Darunavir approved (FDA). 2006: Drug approval — Telbivudine approved (FDA). 2006: Drug approval — Bismuth subcitrate potassium approved (FDA). 2006: Drug approval — Arformoterol approved (FDA). 2006: Drug approval — Human papillomavirus, l1 protein virus like particles approved (FDA). 2006: Drug approval — Mumps virus, live attenuated approved (FDA). 2006: Drug approval — Rotavirus, live approved (FDA). 2006: Drug approval — Rubella virus, live attenuated approved (FDA). 2006: Drug approval — Sinecatechins approved (FDA). 2006: Drug approval — Anidulafungin approved (FDA). 2006: Drug approval — Varicella zoster virus, live attenuated approved (FDA). 2007: Drug approval — Retapamulin approved (FDA). 2007: Drug approval — Doripenem approved (FDA). 2007: Drug approval — Influenza b virus, inactivated neuraminidase approved (FDA). 2007: Drug approval — Influenza b virus, inactivated hemagglutinin approved (FDA). 2007: Drug approval — Influenza a virus, inactivated neuraminidase approved (FDA). 2007: Drug approval — Influenza a virus, inactivated hemagglutinin approved (FDA). 2007: Drug approval — Maraviroc approved (FDA). 2007: Drug approval — Influenza a virus, inactivated whole virion approved (FDA). 2007: Drug approval — Raltegravir approved (FDA). 2008: Drug approval — Etravirine approved (FDA). 2008: Drug approval — Eltrombopag approved (FDA). 2008: Drug approval — Menthol approved (FDA). 2008: Drug approval — Influenza a virus, split virion approved (FDA). 2009: Drug approval — Hepatitis b immune globulin approved (FDA). 2009: Drug approval — Indacaterol approved (FDA). 2009: Drug approval — Streptococcus pneumoniae polysaccharide conjugated to haemophilus influenzae protein d approved (FDA). 2009: Drug approval — Golimumab approved (FDA). 2009: Drug approval — Streptococcus pneumoniae polysaccharide conjugated to tetanus toxoid approved (FDA). 2009: Drug approval — Japanese encephalitis virus, inactivated approved (FDA). 2009: Drug approval — Telavancin approved (FDA). 2009: Drug approval — Besifloxacin approved (FDA). 2009: Drug approval — Artemether approved (FDA). 2009: Drug approval — Benzyl alcohol approved (FDA). 2009: Drug approval — Lumefantrine approved (FDA). 2009: Drug approval — Streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae toxoid approved (FDA). 2009: Drug approval — Influenza b virus, split virion approved (FDA). 2010: Drug approval — Tesamorelin approved (FDA). 2010: Drug approval — Neisseria meningitidis oligosaccharide conjugated to corynebacterium diphtheriae crm197 approved (FDA). 2010: Drug approval — Besilesomab approved (FDA). 2010: Drug approval — Roflumilast approved (FDA). 2010: Drug approval — Ceftaroline fosamil approved (FDA). 2011: Drug approval — Boceprevir approved (FDA). 2011: Drug approval — Spinosad approved (FDA). 2011: Drug approval — Influenza b virus, live attenuated approved (FDA). 2011: Drug approval — Influenza a virus, live attenuated approved (FDA). 2011: Drug approval — Fidaxomicin approved (FDA). 2011: Drug approval — Telaprevir approved (FDA). 2011: Drug approval — Methylene blue cation approved (FDA). 2011: Drug approval — Rilpivirine approved (FDA). 2012: Drug approval — Cobicistat approved (FDA). 2012: Drug approval — Bedaquiline approved (FDA). 2012: Drug approval — Raxibacumab approved (FDA). 2012: Drug approval — Neisseria meningitidis polysaccharide conjugated to tetanus toxoid approved (FDA). 2012: Drug approval — Aclidinium approved (FDA). 2012: Drug approval — Elvitegravir approved (FDA). 2013: Drug approval — Neisseria meningitidis factor h binding protein approved (FDA). 2013: Drug approval — Dolutegravir approved (FDA). 2013: Drug approval — Neisseria meningitidis adhesin a approved (FDA). 2013: Drug approval — Vilanterol approved (FDA). 2013: Drug approval — Vaccinia virus, live modified approved (FDA). 2013: Drug approval — Neisseria meningitidis outer membrane vesicles approved (FDA). 2013: Drug approval — Umeclidinium approved (FDA). 2013: Drug approval — Luliconazole approved (FDA). 2013: Drug approval — Neisseria meningitidis neisserial heparin binding antigen approved (FDA). 2013: Drug approval — Simeprevir approved (FDA). 2013: Drug approval — Sofosbuvir approved (FDA). 2014: Drug approval — Paritaprevir approved (FDA). 2014: Drug approval — Ledipasvir approved (FDA). 2014: Drug approval — Oritavancin approved (FDA). 2014: Drug approval — Ceftolozane approved (FDA). 2014: Drug approval — Peramivir anhydrous approved (FDA). 2014: Drug approval — Olodaterol approved (FDA). 2014: Drug approval — Tavaborole approved (FDA). 2014: Drug approval — Efinaconazole approved (FDA). 2014: Drug approval — Miltefosine approved (FDA). 2014: Drug approval — Dalbavancin approved (FDA). 2014: Drug approval — Vasopressin approved (FDA). 2014: Drug approval — Daclatasvir approved (FDA). 2014: Drug approval — Asunaprevir approved (FDA). 2014: Drug approval — Tedizolid phosphate approved (FDA). 2014: Drug approval — Delamanid approved (FDA). 2014: Drug approval — Dasabuvir approved (FDA). 2014: Drug approval — Ombitasvir approved (FDA). 2015: Drug approval — Avibactam approved (FDA). 2015: Drug approval — Tenofovir alafenamide approved (FDA). 2015: Drug approval — Isavuconazonium approved (FDA). 2016: Drug approval — Bezlotoxumab approved (FDA). 2016: Drug approval — Velpatasvir approved (FDA). 2016: Drug approval — Ephedrine approved (FDA). 2016: Drug approval — Obiltoxaximab approved (FDA). 2016: Drug approval — Grazoprevir anhydrous approved (FDA). 2016: Drug approval — Elbasvir approved (FDA). 2017: Drug approval — Delafloxacin approved (FDA). 2017: Drug approval — Benznidazole approved (FDA). 2017: Drug approval — Letermovir approved (FDA). 2017: Drug approval — Dupilumab approved (FDA). 2017: Drug approval — Avelumab approved (FDA). 2017: Drug approval — Vaborbactam approved (FDA). 2017: Drug approval — Angiotensin ii approved (FDA). 2017: Drug approval — Secnidazole approved (FDA). 2017: Drug approval — Ozenoxacin approved (FDA). 2017: Drug approval — Pibrentasvir approved (FDA). 2017: Drug approval — Hydrogen peroxide approved (FDA). 2017: Drug approval — Glecaprevir approved (FDA). 2017: Drug approval — Voxilaprevir approved (FDA). 2017: Drug approval — Lotilaner approved (FDA). 2018: Drug approval — Eravacycline approved (FDA). 2018: Drug approval — Varicella zoster virus envelope glycoprotein e approved (FDA). 2018: Drug approval — Baloxavir marboxil approved (FDA). 2018: Drug approval — Ibalizumab approved (FDA). 2018: Drug approval — Chimeric yellow fever dengue virus, live attenuated approved (FDA). 2018: Drug approval — Tecovirimat approved (FDA). 2018: Drug approval — Bictegravir approved (FDA). 2018: Drug approval — Plazomicin approved (FDA). 2018: Drug approval — Omadacycline approved (FDA). 2018: Drug approval — Moxidectin approved (FDA). 2018: Drug approval — Rifamycin approved (FDA). 2018: Drug approval — Tafenoquine approved (FDA). 2018: Drug approval — Sarecycline approved (FDA). 2018: Drug approval — Doravirine approved (FDA). 2019: Drug approval — Lefamulin approved (FDA). 2019: Drug approval — Triclabendazole approved (FDA). 2019: Drug approval — Vesicular stomatitis virus encoding ebola virus glycoprotein approved (FDA). 2019: Drug approval — Pretomanid approved (FDA). 2019: Drug approval — Relebactam anhydrous approved (FDA). 2019: Drug approval — Cefiderocol approved (FDA). 2020: Drug approval — Influenza b virus hemagglutinin approved (FDA). 2020: Drug approval — Fostemsavir approved (FDA). 2020: Drug approval — Ansuvimab approved (FDA). 2020: Drug approval — Remdesivir approved (FDA). 2020: Drug approval — Tozinameran approved (FDA). 2020: Drug approval — Artesunate approved (FDA). 2020: Drug approval — Atoltivimab approved (FDA). 2020: Drug approval — Maftivimab approved (FDA). 2020: Drug approval — Odesivimab approved (FDA). 2020: Drug approval — Adenovirus type 26 encoding ebola virus glycoprotein approved (FDA). 2020: Drug approval — Vaccinia virus, modified encoding ebola virus glycoprotein and nucleoprotein approved (FDA). 2020: Drug approval — Nifurtimox approved (FDA). 2020: Drug approval — Influenza a virus hemagglutinin approved (FDA). 2020: Drug approval — Abametapir approved (FDA). 2020: Drug approval — Vibrio cholerae, live attenuated approved (FDA). 2021: Drug approval — Idecabtagene vicleucel approved (FDA). 2021: Drug approval — Sars-cov-2 virus spike protein approved (FDA). 2021: Drug approval — Adenovirus type 26 encoding sars-cov-2 spike glycoprotein approved (FDA). 2021: Drug approval — Sotrovimab approved (FDA). 2021: Drug approval — Regdanvimab approved (FDA). 2021: Drug approval — Ibrexafungerp approved (FDA). 2021: Drug approval — Elasomeran approved (FDA). 2021: Drug approval — Maribavir approved (FDA). 2021: Drug approval — Chimpanzee adenovirus encoding sars-cov-2 spike glycoprotein approved (FDA). 2021: Drug approval — Brincidofovir approved (FDA). 2021: Drug approval — Cabotegravir approved (FDA). 2021: Drug approval — Fexinidazole approved (FDA). 2022: Drug approval — Dengue virus, live attenuated approved (FDA). 2022: Drug approval — Lenacapavir approved (FDA). 2022: Drug approval — Oteseconazole approved (FDA). 2022: Drug approval — Tabelecleucel approved (FDA). 2022: Drug approval — Sars-cov-2 virus, inactivated approved (FDA). 2023: Drug approval — Respiratory syncytial virus pre-fusion glycoprotein f approved (FDA). 2023: Drug approval — Rezafungin approved (FDA). 2023: Drug approval — Bacillus anthracis protective antigen, adsorbed approved (FDA). 2023: Drug approval — Chikungunya virus, live attenuated approved (FDA). 2023: Drug approval — Cantharidin approved (FDA). 2023: Drug approval — Selvacovatein approved (FDA). 2023: Drug approval — Fecal microbiota spores, live approved (FDA). 2023: Drug approval — Retifanlimab approved (FDA). 2024: Drug approval — Amdinocillin pivoxil approved (FDA). 2024: Drug approval — Ceftobiprole medocaril free acid approved (FDA). 2024: Drug approval — Respiratory syncytial virus pre-fusion glycoprotein f mrna approved (FDA). 2024: Drug approval — Polihexanide approved (FDA). 2024: Drug approval — Berdazimer sodium approved (FDA)

What's being tested now

2000: 6 trials started2001: 8 trials started2002: 12 trials started2003: 1 trials started2004: 4 trials started2005: 3 trials started2006: 3 trials started2007: 5 trials started2008: 4 trials started2009: 14 trials started2010: 16 trials started2011: 16 trials started2012: 10 trials started2013: 19 trials started2014: 31 trials started2015: 33 trials started2016: 37 trials started2017: 58 trials started2018: 64 trials started2019: 101 trials started2020: 228 trials started2021: 237 trials started2022: 350 trials started2023: 607 trials started2024: 1062 trials started2025: 1341 trials started2026: 1421 trials started20002010202020261421

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 5115 active Acquired Immunodeficiency Syndrome trials on Clin2 →

Where we are

AI-generated

Neonatal sepsis and other bacterial infections in newborns are curable or preventable in most cases when modern medicine is available. Early antibiotics and supportive care in a newborn unit can turn a mostly fatal infection into a survivable one. Maternal immunization and clean cord care can prevent tetanus. Deaths have fallen substantially over recent decades in settings with access to care, though inequities and antibiotic resistance remain serious barriers. A turning point was the 1965 approval of ampicillin, which gave doctors a reliable treatment for many bacterial infections. Research continues: more than 5,000 clinical trials have started in the past five years, including nearly 500 in phase 3. The challenge is not the absence of effective tools, but ensuring every newborn can reach them.

Can neonatal sepsis be cured?
Yes. For most bacterial infections, early antibiotics and supportive care in a newborn unit can cure the infection. Without timely treatment, the risk of death is high, which is why access to care matters.
Is neonatal sepsis preventable?
Many cases are preventable. Maternal immunization against tetanus, clean cord care, and prompt treatment of maternal infections reduce risk. Good hygiene and infection control in hospitals also help.
Are new treatments being researched?
Yes. Over 5,000 clinical trials have begun in the last five years, including nearly 500 in phase 3. This points to active work on better antibiotics, diagnostics, and prevention strategies.
Why is access to care important?
Because outcomes depend heavily on timely treatment. In settings with limited healthcare, neonatal sepsis can be fatal, while in well-equipped hospitals it is often survivable. Improving access is key to reducing deaths.

Related

Neonatal preterm birthNeonatal encephalopathy due to birth asphyxia and traumaHemolytic disease and other neonatal jaundiceOther neonatal disorders

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.